The 2023 ESC Clinical Practice Guidelines
📚Cardiomyopathies
📚Acute Coronary Syndromes
📚Cardiovascular Disease and Diabetes
📚Endocarditis
These new recommendations for you and your patients
@escardio#ESCCongress
Mechanisms of benefits of #SGLT2i in #HFpEF and the Multifaceted Benefits of SGLT2i
📌Regulation of blood sugar, blood pressure, and kidney disease progression.
📌Induction of nutrient-deprivation responses leading to increased ketosis and erythropoietin.
📌Improvement in
🔥New Recommendation of HFpEF from 2022 AHA/ACC/HFSA Guideline for the Management of #HeartFailure#ACC22
New recommendations for #HFpEF are ;
#SGLT2i (Class 2a)
#MRAs (Class 2b)
#ARNi (Class 2b)
#ARB (Class 2b)
Routine use of nitrates or #PDE-5 inhibitors (Class 3:No Benefit)
In patients with #HFrEF, quadruple therapy with #ARNI, #BB, #MRA, and #SGLT2i has the potential to increase lifespan 2 to 3 years when used instead of historic double or triple drug regimens
Mean Projected Survival:
💊Quadruple Therapy - 10.99 years (9.64-12.24)
💊Triple
Prophylactic #Rivaroxaban Therapy for LV Thrombus After Anterior #STEMI
This study supports the short-duration addition of low-dose rivaroxaban (2.5 mg BD ) to #DAPT to prevent LVT formation in patients with anterior STEMI who had undergone #PCIjacc.org/doi/10.1016/j.…
